Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Other Operating Expenses (2016 - 2025)

Protalix BioTherapeutics (PLX) has 10 years of Other Operating Expenses data on record, last reported at $22000.0 in Q3 2025.

  • For Q3 2025, Other Operating Expenses fell 98.47% year-over-year to $22000.0; the TTM value through Sep 2025 reached -$3.9 million, down 371.92%, while the annual FY2019 figure was $77000.0, 96.51% down from the prior year.
  • Other Operating Expenses reached $22000.0 in Q3 2025 per PLX's latest filing, up from -$3.9 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $1.4 million in Q3 2024 and bottomed at -$3.9 million in Q2 2025.